These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 22321279)

  • 1. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
    Shanmugam E; Doss CR; George M; Jena A; Rajaram M; Ramaraj B; Anjaneyan K; Kanagesh B
    Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.
    Salahudeen AK; Ali N; George M; Lahoti A; Palla S
    Cancer; 2014 Mar; 120(5):744-51. PubMed ID: 24895288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
    Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
    Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
    Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS;
    Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
    Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
    Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
    J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
    Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan.
    Plosker GL
    Drugs; 2010 Mar; 70(4):443-54. PubMed ID: 20205486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.